The thrombotic thrombocytopenic purpura (TTP) is a multi-systemic microvascular disorder caused by imbalance between the formation of unusually large von Willebrand factor (vWF) multimers and cleaving proteinase ADAMTS13. TTP is used to present a constellation of symptoms of microangiopathic hemolytic anemia (MAHA), characteristic peripheral blood smear findings, fever, renal failure and neurologic abnormalities. It is sometimes characterized by combination of atypical clinical features, make it difficult to differentiate from other diseases such as idiopathic thrombocytopenic purpura (ITP), disseminated intravascular coagulation (DIC) and sepsis. Specifically, the diagnosis is challenging when TTP is manifested with multifocal cerebral infarction because many clinical conditions could result in. With the development of recent molecular diagnostics based on the ADAMTS 13 assay, the diagnosis rate of TTP has been refined compared to the past. However, the point that needs to be careful in the diagnosis of TTP is to consider the low sensitivity of ADAMTS 13 assay although it showed high specificity. Therefore, in the case of clinical presumptive TTP, the ADAMTS 13 assay is often demonstrated negative results. Although it is certain that the ADAMTS 13 assay is an important molecular method for diagnosing TTP, the availability of assay is limited to special lab and it takes a lot of time for diagnosis. Hence, it is not reasonable to depend on ADAMTS 13 assay in the diagnosis of TTP, but the diagnosis based on clinical circumferences is more judicious not to delay the treatment.

A recent targeted therapy with rituximab has been tried to alleviate the excessive immunologic responses in TTP, the results is currently anecdotal. Thus, therapeutic plasmapheresis (TPE) has been played a pivotal role in the treatment of TTP. In fact, prior to plasmapheresis was applied to treatment, the mortality rate of TTP had been reached 90%, but it decreased to less than 20% after introduction of plasmapheresis. In this report, clinical vignette of
postoperative CNS-involved TTP treated by plasmapheresis and related literature would be reviewed.

**CASE**

A 78-year-old woman with the history of cerebral infarction three years ago, visited hospital because of right hip pain after slip down episode. In physical and radiologic examination, right hip fracture was diagnosed. There were no noticeable abnormalities in blood chemistry, cardiopulmonary and neurologic examination. Consequently, she underwent bipolar hemiarthroplasty (BPHA).

After 5-day recovery, she presented slightly decreased consciousness and disorientation without prominent neurologic deficits. In diffusion-weighted MR images, no diffusion-restricted lesion revealed, however, cerebral blood flow delay was noted in time-to-peak (TTP) images (Fig. 1A). Unfortunately, global aphasia and hypobulic compliance were immediately followed by period of consistent deterioration of consciousness. Multifocal cerebral infarction was noted over frontal, temporal lobe and cerebellar hemisphere in diffusion-weighted image and ADC map (Fig. 1B). However, there were no evidence of thromboembolic source. Cerebral vasculature including carotid artery was patent without luminal irregularities in contrast-enhanced MR angiography. Additionally, cardiac arrhythmia had not been reported during hospital course in continuous EKG monitoring. At presentation, her platelet count was $13 \times 10^9/L$ with mild normochromic normocytic anemia (hemoglobin was 10.3 g/dL). Initial blood smear showed occasional schistocytes with true thrombocytopenia (Fig. 2). On the following day, unexplained fever was developed and thrombocytopenia steadily worsened to $2.5 \times 10^9/L$. At same time, oliguria and blood pressure drop was sustained and revealed due to non-territorial cardiac dysfunction in echocardiography (Fig. 3). Cumulative ly, the diagnosis of thrombotic thrombocytopenic purpura (TTP) was considered. She continued to deteriorate further with severe respiratory distress and did not improve despite intensive respiratory and circulatory supports including inotropic agents. The

---

**Fig. 1.** (A) MR findings of the first day of clinical deterioration. Multiple acute embolic infarction in left temporoparietal lobe and deep white matter. Old infarcted lesions were also denoted by DWI-FLAIR mismatch in bilateral temporoparietal lobe and left frontal lobe. The peak time of cerebral blood flow was prolonged at left temporoparietal lobe. (B) MR findings during plasmapheresis. Re-infarction at left temporoparietal lobe and new multiple embolic infarction at bilateral frontal, right temporoparietal, centrum semiovale, and left cerebellum. DWI, diffusion-weighted image; ADC, apparent-diffusion coefficient; CT, computed tomography; FLAIR, fluid-attenuated inversion recovery; TTP, time to peak; MRA, magnetic resonance angiograph.

**Fig. 2.** Peripheral blood smear (Wright stain, ×1,000). (A) Before plasmapheresis. Frequent schistocytes, spherocytes, and absence of platelets. (B) During plasmapheresis. Occasional schistocytes, spherocytes, and presence of platelets. (C) After plasmapheresis. Disappearance of schistocytes, spherocytes, and adequate platelets.

---

www.e-jnic.org
schistocyte count (based on classical triangular hyperchromatic RBCs) was slightly increased after a serial investigation. Direct anti-globulin test (DAT) was negative. Serial blood investigations noted worsening of anemia (8.4 g/dL) and thrombocytopenia (11 × 10^9/L) with reticulocytosis (7.5%). Lactate dehydrogenase (LDH) was 929 U/L (high) and liver function test (LFT) was abnormal. AST, ALT, and total bilirubin were 95 U/L, 99 U/L, and 32 umol/L, respectively. Results of coagulation screening tests (PT, APTT, and fibrinogen) were normal. D-dimer was elevated (3.68 ug/mL). Autoimmune profiles were negative for antinuclear antibody (ANA) and double stranded DNA (dsDNA). Under impression of TTP, therapeutic plasmapheresis was performed daily for 10 days with goal of normalization of platelet count and LDH.

Serial peripheral blood smear showed a reduced number of schistocytes in the blood film with increasing platelet count after plasmapheresis. Her condition was steadily improved, and she was transferred to general ward after 20 days of ICU admission following sustained normalization of platelet count, hemoglobin, and LDH levels (Fig. 4).

**DISCUSSION**

**Pathogenesis**

TTP is classified into congenital and acquired TTP. The congenital TTP accounts for less than 5% of total TTP and is usually presented at birth or in childhood. Congenital TTP occurs in an autosomal recessive manner by the homozygous mutation of the ADAMTS 13 gene located in the chromosome 9q34 locus. Most TTP is the form of acquired TTP. The von Willebrand factor (vWF), a glycoprotein secreted from vascular endothelial cells as a very large polymeric form, induces platelet adhesion and aggregation in vascular lesions. The ADAMTS 13, one of the metalloproteinases presents in plasma, cleaves the shear-induced conformational unfolded vWF. By clearing vWF before fully activating vWF formation by shear stress, ADAMTS 13 inhibits excessive vWF-mediated platelet aggregation. Autoimmune TTP is caused by the production of anti-ADAMTS 13 antibody, which inhibits the proteolytic activity of ADAMTS 13. The anti-ADAMTS 13 antibody is usually an IgG type, binds to ADAMTS 13 and accelerates its removal from the plasma by opsonization or by an unknown mechanism. Because of ADAMTS 13 deficiency, uncontrolled large vWF polymer is formed and acts as a pivotal player in the manifestation of TTP clinical symptoms. Although the ADAMTS 13 deficiency is not consistently observed in all TTP patients, this is currently considered a model to elucidate the mechanisms of TTP.

There have been known several predisposing factors that cause TTP as well as ADAMTS 13 deficiency (Table 1). Vascular endothelial damage is another central factor leading to thrombotic microangiopathy and could be caused by drugs, infections, toxins, and other clinical conditions that cause vascular endothelial damage. The patient in this report presented renal impairment and neurologic abnormalities after one week of hip hemiarthroplasty (BPHA). Although the mechanism how orthopedic surgery induces TTP is uncertain, it is not uncommon for TTP to occur after orthopedic surgery. There was no drug history that could induce the TTP except for orthopedic surgery.

**Diagnosis**

Paradoxically, thrombotic and thrombocytopenic-associated symptoms are coincidently occurred in TTP. Organ involvement by thrombosis in microvasculature manifests symptoms such as renal impairment, cardiac ischemia, central neurologic deficit. On the contrary, the hemorrhage symptoms including epistaxis, bruising, petechia, hematuria, hemoptysis, etc. are resulted from secondary thrombocytopenia caused by consumptive thrombocytopenia (Fig. 3).
Characteristically, cardiac ischemia was presented as non-territorial pattern associated with multi-focal embolism in small coronary vessels. Multifocal cerebral infarction caused by small vessel occlusion was also observed in diffusion weighted images. Given that there were no evidences of atrial fibrillation and carotid artery thrombosis, the source of microembolism was not evident. In the laboratory test, the compatible findings for MAHA were observed and abundant schistocytes were revealed in peripheral blood smear. Direct antiglobulin test was negative. Severe thrombocytopenia, platelet count below 20,000/ul and mildly prolonged prothrombin time (PT) within 5 seconds of upper limit were also revealed. These are reasonable findings indicating TTP rather than DIC. The viral antigen and autoantibody test were also negative.

Recent studies have recommended measuring the ADAMTS 13 activity before treatment. The ADAMTS 13 assay includes cleaving activity of ADAMTS 13, neutralizing or non-neutralizing autoantibody measurement. The severely decreased ADAMTS 13 activity ( < 5%) or the presence of IgG antibody to ADAMTS 13 establish the diagnosis of TTP. In case of severe ADAMTS 13 activity ( < 5%), the diagnostic specificity for TTP reaches to 90%. However, there are limitations in the ADAMTS 13 assay-guided treatment of TTP because the low sensitivity (60%), low accessibility of tests and lagging time to report the results. Patients in this case were diagnosed as TTP based on clinical and laboratory findings prior to confirmation of ADAMTS 13 assay.

### Treatment
Two-thirds of cases of TTP patients are sporadic TTP, and one-third of patients tend to relapse after TTP remission. Chronic recurrent form of TTP may be associated with genetic predisposition and autoantibody. On the other hand, in cases which link to malignancy or transplantation, they are usually presented as acute episode.

In the past, therapeutic splenectomy was performed in patients with refractory or chronic recurrent TTP. Currently, there are other treatments available. One such treatment involves therapeutic plasmapheresis (TPE). Microangiopathic hemolysis and thrombocytopenia were also improved response to TPE demonstrated by the increased platelet, normalization of reticulocyte and LDH. Delayed deterioration of renal function was noted during TTP course. TPE, therapeutic plasmapheresis; LDH, lactated dehydrogenase.

Fig. 4. Dynamic changes of peripheral blood profiles and chemistries during TTP progress. Idiopathic fever (A) was alleviated after therapeutic plasmapheresis (TPE). Microangiopathic hemolysis and thrombocytopenia were also improved response to TPE demonstrated by the increased platelet (B), normalization of reticulocyte (C) and LDH (D). Delayed deterioration of renal function (E) was noted during TTP course. TPE, therapeutic plasmapheresis; LDH, lactated dehydrogenase.

### Table 1. Conditions and diseases associated with thrombotic thrombocytopenic purpura

| Conditions and Diseases |
|------------------------|
| Pregnancy and postpartum |
| Drugs (quinine and quinidine, ticlopidine, clopidogrel, cyclosporine, interferon-a, statins) |
| Chemotherapy (cisplatin, mitomycin, gemcitabine) |
| Allogenic bone marrow transplantation |
| Connective tissue diseases (Marfan syndrome, lupus erythematosus and scleroderma) |
| Post-surgery (cardiac surgery and orthopedic surgery) |

Pregnancy and postpartum
Drugs (quinine and quinidine, ticlopidine, clopidogrel, cyclosporine, interferon-a, statins)
Chemotherapy (cisplatin, mitomycin, gemcitabine)
Allogenic bone marrow transplantation
Connective tissue diseases (Marfan syndrome, lupus erythematosus and scleroderma)
Post-surgery (cardiac surgery and orthopedic surgery)
ter treatment options than splenectomy in the aspect of surgical risk-benefit, but the splenectomy had been shown a firm effect to prevent recurrence of TTP. There were retrospective studies showed the remission rate of the splenectomy after TTP episode. When observing average 111 months (range, 9 to 230 months), relapse-free survival reached 10 years and relapse rate was 17% when splenectomy was done. Currently one of the most important treatment methods of TTP is daily plasmapheresis and it has been reported that the mortality rate is decreased by about 90 to 20%. It restores ADAMTS13 by removing autoantibody from the blood. Recently, early plasmapheresis is recommended because in cases that plasmapheresis is delayed, usually need a large volume of plasma infusion. The total period and number of plasmapheresis required for TTP remission are highly variable depending on the patients, however, obviously long period of plasmapheresis is needed especially in the antibody-mediated TTP. Daily exchanges should last at least two days even after reaching the normal level of platelet count (> 150 × 10^9/l). Transfusion is one of the essential adjunctive therapies during therapeutic plasmapheresis. Red cell transfusion should be administered according to clinical need, especially when anemia is getting worse. During active hemolysis, folate supplementation could be also required. Unless TTP is associated with life-threatening hemorrhage, platelet transfusion is not routinely indicated. Prophylactic use of LMWH to prevent thrombosis in high risk patients is recommended once the Platelet count reaches above 50 × 10^9/l.

Steroid is widely used during plasmapheresis at early period of acute immune TTP. High dose steroids were reported to show minimal side effects and improve patient prognosis. However, there is no randomized clinical trial proving that a combination of plasmapheresis and steroid is superior to plasmapheresis alone.

**Relapse**

Relapse is defined by TTP recurrence after 30 days from initial episode. The TTP relapse is known to occur in 20 to 50% of total TTP cases. Canadian Apheresis group reported 36% relapse rate over a 10 year follow up of TTP patients.

Patients with ADAMTS 13 activity less than 10% or in which anti-ADAMTS 13 antibody is positive in blood during remission period are reported to show a 3-fold higher recurrence rate over 1 year. In case that ADAMTS 13 activity was 5% or less, the recurrence rate reached 38.5%, but in case of 15% or more, only 5% of the patients relapsed in previous report. The use of rituximab during acute TTP episode was reported to reduce the risk of relapse. In patients with ADAMTS 13 activity less than 5%, elective rituximab therapy could normalize ADAMTS 13 activity and decreased relapse rate.

Cumulatively, TTP patients are recommended to counsel the symptoms and dangers of recurrence and monitor ADAMTS 13 activity periodically.

**Patient Consent**

The patient and guardian have consented to the submission of the case report for submission to the KJCCM.

**NOTES**

**Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

**Acknowledgements**

None.

**REFERENCES**

1. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927–1935.
2. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:654–66.
3. Lämmle B, Kremer Hovinga J, Stadt JD, Mansouri Taleghani B, Alberio L. Thrombotic thrombocytopenic purpura. Hematol J 2004;5 Suppl 3:S6–11.
4. Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008;141:651–8.
5. Gangemi S, Allegra A, Sciarrone P, Russo S, Cristani M, Gerace D, et al. Effect of therapeutic plasma exchange on plasma levels of oxidative biomarkers in a patient with thrombotic thrombocytopenic purpura. Eur J Haematol 2015;94:368–373.
6. Clark WF, Rock G, Barth D, Arnold DM, Webert KE, Yenson PR, et al, members of Canadian Apheresis Group. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed refractory thrombotic thrombocytopenic purpura treated with rituximab. Br J Haematol 2015;170:208–217.
7. Vesely SK. Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy. J Thromb Haemost 2015;13(Suppl 1):S216–S222.
8. Han B, Page EE, Stewart LM, Deford CC, Scott JG, Schwartz LH, et al. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J He-
matol 2015;90:709–14.
9. Cataland SR, Wu HM. Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use. J Thromb Haemost 2015;13 Suppl 1:S223–9.
10. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013;11:481–90.
11. Cataland SR, Scully MA, Paskavitz J, Maruff P, Witkoff L, Jin M, et al. Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol 2011;86:87–89.
12. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773–1777.
13. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, et al, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012;158:323–335.